About Seer
Seer is a company based in San Francisco (United States) founded in 2017. It operates as a Product-as-a-Service and HealthTech. Seer has raised $127.5 million across 7 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 134 employees as of December 31, 2024. Seer offers products and services including Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center. Seer operates in a competitive market with competitors including Metabolon, Cyrus Biotechnology, Maze Therapeutics, Vividion Therapeutics and Alector, among others.
- Headquarter San Francisco, United States
- Employees 134 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Seer, Inc.
-
Annual Revenue
$13.95 M (USD)-8.13as on Dec 31, 2024
-
Net Profit
-$86.6 M (USD)-0.37as on Dec 31, 2024
-
EBITDA
-$94.15 M (USD)5.25as on Dec 31, 2024
-
Total Equity Funding
$127.5 M (USD)
in 7 rounds
-
Latest Funding Round
$55 M (USD), Series D
Jul 22, 2020
-
Investors
Fidelity Investments
& 10 more
-
Employee Count
134
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Seer
Seer is a publicly listed company on the NASDAQ with ticker symbol SEER in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Seer
Seer offers a comprehensive portfolio of products and services, including Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center.
Deep, rapid, unbiased proteomics analysis at scale provided.
Proteomics data is analyzed quickly and easily here.
White-glove service programs for proteomics are offered now.
People of Seer
Unlock access to complete
Unlock access to complete
Funding Insights of Seer
Seer has successfully raised a total of $127.5M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $55 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Seer
Seer has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked |
Investor details for Seer
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seer
Investment portfolio details for Seer
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Seer
Detailed financials for Seer
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Seer Comparisons
Peer comparison for Seer
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Seer
Seer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Cyrus Biotechnology, Maze Therapeutics, Vividion Therapeutics and Alector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
Detailed competitors of Seer
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Seer
Complete news archive for Seer
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seer
Seer was founded in 2017.
Seer is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Seer is a funded company, having raised a total of $127.5M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Seer is 134.
Annual revenue of Seer is $13.95M as on Dec 31, 2024.
Seer, Inc. is dedicated to pioneering innovative technologies for proteomics research. The company is engaged in developing tools like the Proteograph Product Suite to enable deep, rapid, and unbiased proteomics at scale. Solutions such as the Proteograph Analysis Suite are provided for efficient data analysis. Operating in the healthcare and biotechnology sectors, Seer aims to eliminate barriers in proteomics, empowering the scientific community to achieve exceptional outcomes. Their technology is utilized by top researchers and featured in numerous scientific publications. The mission is centered on decoding the proteome to improve human health globally.
Seer's top competitors include Alector, Maze Therapeutics and Metabolon.
Seer offers Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center.
Yes, Seer is publicly traded on NASDAQ under the ticker symbol SEER.
Seer has 11 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Aju IB Investment, and HBM Healthcare Investments.
The ticker symbol of Seer is SEER on NASDAQ.